This year introduces the DACH Bioprocessing Excellence Awards, recognising manufacturing innovation, operational excellence, and leadership across cell & gene therapy, biologics, and oligos & peptides.
Day 1 | 17 February 2027 |
||
|
|
|
|
Commercialising Cell & Gene Therapies: Scaling for Global Success
|
The Future of Biologics Manufacturing: Building Scalable, Resilient and Intelligent Operations
|
Current State of Oligo & Peptides Manufacturing in DACH Region
|
| Networking Break | ||
|
Scaling Cell Therapy Manufacturing
|
Next-Generation Upstream Manufacturing
|
Analytical Characterization & Quality Control
|
| Lunch | ||
|
Overcoming Bottlenecks in Viral Vector Manufacturing
|
Optimising Downstream Throughput
|
Formulation and Delivery Strategies
|
| Networking Break | ||
|
Industry Roundtables: The Future of CGT Manufacturing
|
Industry Roundtables: Solving Tomorrow's Manufacturing Challenges Today
|
Industry Roundtables: The Future of Tides
|
| End of Conference Day 1 | ||
Day 2 | 18 February 2027 |
||
|
|
|
|
|
Bridging the CGT Scale-Up & Tech Transfer Gap
|
Advancing CMC for Next-Generation Biologics
|
Process Development & Scale-Up
|
| Networking Break | ||
|
Quality, GMP & Regulatory Control in CGT Manufacturing
|
Novel Approaches to Biosafety Testing
|
Supply Chain and Outsourcing Strategies
|
| Lunch | ||
|
Novel Biosafety and Contamination
|
AI, Digitalisation & Smart Biomanufacturing
|
Scaling Oligo & Peptide Manufacturing
|
| Networking Break | ||
|
Supply Chain, Logistics & Commercial Readiness
|
Building Flexible Facilities for a Multi-Modality Future
|
CMC Strategy and Fill-Finish for Oligos & Peptides
|
| End of Conference | ||
DAY 1
17 February 2027
08:50
Chairman’s Welcome Address
Nicoletta Loggia
Chief Technology Officer, Orchard Therapeutics, Switzerland
09:00
Scaling Viral Vector & Cell Therapy Manufacturing for Commercial Readiness
- Overcoming scale-up bottlenecks in viral vector production (lentiviral, AAV)
- Managing process consistency from development to GMP manufacturing
- Manufacturing considerations across T-cell, NK-cell, and CD34 stem cell therapies
- Bridging the gap between small-scale development and industrial production
Nicoletta Loggia
Chief Technology Officer, Orchard Therapeutics, Switzerland
09:30
Solution Provider
Reserved for Solution Provider
10:00
Panel Discussion
Building Sustainable CGT Business Models: From Clinica
- Impact of funding constraints and milestone-driven investment
- Cost of goods and manufacturing scalability challenges
- Ensuring long-term operational and commercial sustainability
- Aligning manufacturing strategy with market access and growth
Panelists
Chris Baldwin
Vice President, Manufacturing and Supply, Resolution Therapeutics, UK
11:10
Scaling Non-Viral T-Cell Engineering: Bridging Process Development and GMP Manufacturing (TBC)
- Translation from small-scale development to clinical manufacturing
- Large-scale CRISPR knock-in and knock-out
- Maintaining editing efficiency, viability and cell quality
- Reproducibility across different donors and starting materials
Gulbengu Kuzgun Yuksel
Network Head of Quality Cell & Gene Therapy, Roche, Switzerland
11:40
Solution Provider
Reserved for Solution Provider
12:10
Scaling CAR-T Manufacturing: From Clinical Success to Commercial Delivery
- Overcoming manufacturing bottlenecks in autologous CAR-T production
- Improving vein-to-vein timelines through process optimisation
- Increasing manufacturing capacity while maintaining product quality
- Preparing CAR-T platforms for sustainable commercial supply
14:00
Scaling Viral Vector Manufacturing: From Development to GMP Production
- Addressing scale-up challenges in lentiviral and AAV production
- Managing process variability between R&D and GMP environments
- Bridging development processes with commercial manufacturing requirements
- Reducing risk during tech transfer and engineering runs
14:30
Solution Provider
Reserved for Solution Provider
15:00
Improving Yield, Consistency & Cost Efficiency in Viral Vector Production
- Enhancing process robustness and reproducibility at scale
- Tackling low yields in complex vector manufacturing processes
- Optimising upstream and downstream performance for efficiency gains
- Balancing cost pressures with clinical and commercial demand
16:00
Roundtable Discussion
Can CGTs Become Truly Commercially Viable?
Fixing the Scale-Up & Tech Transfer Gap in CGT
What Does “GMP” Really Mean for Early-Phase ATMPs?
Industrialising CGT: Automation vs Practical Reality
Building Scalable CGT Manufacturing Models for the Next Decade (TBC)
Gulbengu Kuzgun Yuksel
Network Head of Quality Cell & Gene Therapy, Roche, Switzerland
DAY 2
18 February 2027
08:50
Chairman’s Welcome Address
09:00
Why CGT Tech Transfer Fails — From R&D to GMP Reality
- Fundamental mismatch between lab-scale and GMP manufacturing environments
- Limited opportunity for full-scale optimisation due to cost and material constraints
- Environmental and operational differences between development and production sites
- Hidden failure points emerging only during GMP execution
Marion Hitchcock
Managing Director Gene & Cell Therapies Incubator, Bayer, Germany
09:30
Solution Provider
Reserved for Solution Provider
10:00
Manufacturing Strategies Across CD34 Stem Cell, T Cell & NK Cell Therapies
- Platform-specific manufacturing challenges across CD34 stem cells, T cells, and NK cells
- Optimising process development and scale-up for different cell therapy modalities
- Technology transfer considerations from clinical to commercial manufacturing
- Ensuring process robustness, comparability, and manufacturing consistency across diverse cell therapy platforms
11:10
Rethinking QA in CGT — From End-Point Release to Continuous Quality Control
- Shift from traditional end-point QC to in-process quality monitoring
- Real-time process data to prevent deviations instead of reacting via CAPA
- High variability in CGT driving increased deviation and investigation burden
- Balancing speed-to-patient with GMP compliance requirements
11:40
Solution Provider
Reserved for Solution Provider
12:10
Navigating GMP & Regulatory Complexity in Cell & Gene Therapy
- Non-harmonised expectations across EMA vs FDA and global regulators
- Evolving GMP expectations for early-phase vs commercial CGT manufacturing
- Assay validation, comparability, and starting material scrutiny challenges
- Regulatory uncertainty during tech transfer from academic to GMP environments
14:00
Panel Discussion
How can CGT manufacturers strengthen biosafety controls without slowing development?
- Managing contamination risk across donor material, starting materials, viral vectors, and open processing steps
- Balancing rapid methods, assay sensitivity, and GMP/regulatory expectations
- Strengthening investigation and decision-making pathways when atypical results arise
- Building scalable contamination-control strategies as programmes move from early clinical to commercial supply
14:30
Solution Provider
Reserved for Solution Provider
15:00
Building a Phase-Appropriate Biosafety Strategy for Cell and Gene Therapy Manufacturing
- Defining biosafety-testing needs according to modality, process risk, and clinical stage
- Integrating cell-bank, raw-material, in-process, and product testing into one coherent control strategy
- Reducing turnaround-time risk while maintaining confidence in product safety and quality
- Preparing biosafety methods and controls for tech transfer, scale-up, and commercial readiness
16:00
Managing Critical Material Shortages in CGT Manufacturing
- Viral vectors, plasmids and raw material bottlenecks
- Long lead times and limited supplier base
- Impact of material constraints on GMP production timelines
- Practical mitigation strategies used by manufacturers today
16:30
What Breaks When CGTs Move from Clinical to Commercial Supply?
- Tech transfer failures impacting supply continuity
- Scaling manufacturing networks under GMP constraints
- Misalignment between development timelines and manufacturing reality
- Operational challenges in sustaining commercial supply
DAY 1
17 February 2027
08:50
Chairman’s Welcome Address
Nicoletta Loggia
Chief Technology Officer, Orchard Therapeutics, Switzerland
09:00
Commercial Manufacturability by Design: Why Scale-Up Success Starts During Development
- Integrating manufacturability into early development
- Bridging process development and commercial manufacturing
- Embedding QbD and process understanding from day one
- Avoiding costly scale-up and tech transfer failures
09:30
Solution Provider
Reserved for Solution Provider
10:00
Panel Discussion
The Biologics Factory of 2030: AI, Digital Twins and the Future of Manufacturing Excellence
- Where AI is delivering value today
- Digital twins versus reality
- PAT and real-time process understanding
- Building GMP-compliant digital manufacturing environments
Panelists
Daniel Hurni
Supply Chain Enterprise Capability Lead, Roche, Switzerland
Dr. Ulrich Rümenapp
Senior Biotech Program Lead, Bayer, Germany
Bettina Knapp
Head of Digital Operations Drug Substance, Boehringer Ingelheim Pharma, Germany
11:10
The Intensification Paradox: When More Upstream Productivity Creates Downstream Problems
- Are upstream teams optimising the wrong KPIs?
- When increased titres overwhelm downstream capacity
- Facility implications of intensified processes
- Balancing yield, quality and throughput
11:40
Solution Provider
Reserved for Solution Provider
12:10
AI-Driven Upstream Development: Can Digital Twins Predict Scale-Up Success?
- Current state of digital twin deployment
- Predictive cell culture modelling
- AI-assisted process development
- Separating hype from practical value
14:00
Maximising Yield Without Compromising Quality in Commercial Biologics Manufacturing
- Reducing product loss across the manufacturing process
- Balancing yield and product quality
- Process robustness at commercial scale
- Cost-of-goods optimisation
14:30
Solution Provider
Reserved for Solution Provider
15:00
From Process Understanding to Product Quality: Linking CPPs, CQAs and Downstream Performance
- Process understanding strategies
- Managing critical quality attributes
- Data-driven validation
- Regulatory expectations for commercial manufacturing
16:00
Roundtable Discussion
Integrating AI into GMP Environments Without Compromising Compliance (TBC)
Alessio Epifanio
Director, Environmental Health, Safety & Sustainability, J&J Innovative Medicine,, Italy
Bridging the Gap Between Process Development and Commercial Manufacturing (TBC)
Daniel Hurni
Supply Chain Enterprise Capability Lead, Roche, Switzerland
Biomanufacturing Without Silos: Connecting Development, Manufacturing, Quality and Supply Chain
Building Supply Chain Resilience in an Era of Geopolitical Uncertainty
Beyond the Contract: What Does a True Manufacturing Partnership Look Like?
DAY 2
18 February 2027
08:50
Chairman’s Welcome Address
09:00
Platform Processes Are Not Plug-and-Play: Adapting CMC Strategies for Complex Biologics
- When platform processes accelerate development
- When customisation becomes essential
- CMC considerations for ADCs and emerging modalities
- Balancing speed and flexibility
09:30
Solution Provider
Reserved for Solution Provider
10:00
Quality by Design in Practice: Strengthening Process Understanding for Commercial Scale-Up
- Building process understanding early
- Linking CPPs and CQAs
- Supporting comparability and validation
- Regulatory expectations for scale-up
11:10
Building a Risk-Based Biosafety Testing Strategy for Complex
- Defining biosafety-testing requirements based on product modality, process risk, and development stage
- Integrating rapid and compendial methods without compromising data integrity or regulatory acceptability
- Establishing clear decision pathways for atypical results, investigations, and batch-impact assessment
- Aligning development, quality, manufacturing, and external testing partners around a coherent testing strategy
Baerbel Grossmann
Associate Director Global Regulatory Affairs CMC Biologics, Sanofi, Germany
11:40
Solution Provider
Reserved for Solution Provider
12:10
From Cell Bank to Commercial Supply: Strengthening Contamination Control Across the Biologics Lifecycle
- Building viral-safety strategy into cell-bank qualification
- Identifying contamination risks across the manufacturing process
- Using monitoring and trend analysis to strengthen control
- Protecting supply continuity during investigations and scale-up
14:00
Panel Discussion
Smart Manufacturing for a Sustainable Future (TBC)
- AI and digital tools for greener manufacturing operations
- Improving resource efficiency through connected manufacturing
- Building resilient and sustainable production networks
- Measuring sustainability through real-time operational insights
Alessio Epifanio
Director, Environmental Health, Safety & Sustainability, J&J Innovative Medicine,, Italy
14:30
Solution Provider
Reserved for Solution Provider
15:00
Digital Twins for Bioprocess Development and Manufacturing: Are We There Yet?
- Current capabilities and limitations
- Process modelling and multivariate analysis
- Predicting scale-up performance
- Moving from equipment-level models to end-to-end process simulation
16:00
Single-Use vs Stainless Steel: What Will Define the Next Generation of Biomanufacturing?
- Drivers behind the shift toward single-use technologies
- When stainless steel still makes strategic sense
- Supporting flexible manufacturing models
- Implications for scale, cost, and operational efficiency
16:30
Designing Facilities for Process Intensification and Perfusion Manufacturing
- Facility implications of intensified processing
- Supporting perfusion at commercial scale
- Infrastructure requirements for higher productivity
- Balancing flexibility and capacity
DAY 1
17 February 2027
08:50
Chairman’s Welcome Address
Nicoletta Loggia
Chief Technology Officer, Orchard Therapeutics, Switzerland
09:00
Challenges in the Synthesis of Isotopically Labelled Peptides
Volker Derdau
Head Center of Excellence Isotope Chemistry, Senior Distinguished Scientist, Sanofi, Germany
09:30
Solution Provider
Reserved for Solution Provider
10:00
Panel Discussion
Overcoming Operational and Regulatory Challenges in the DACH Region
- Navigating regional regulatory expectations for complex oligos and peptides
- Strategies to address supply chain risks and raw material availability
- Integration of digital tools and analytics for process control and quality assurance
- Best practices for cross-site technology transfer and operational excellence
Panelists
Karoline Bechtold-Peters
Director Science & Technology - Scientific Office/Drug Product Development/Global Biologics & CGT, Novartis, Switzerland
11:10
Advanced Analytics for TIDES Molecules
- LC-MS methods for complex peptides and oligonucleotides
- Impurity profiling and identification of critical quality attributes
- Stability-indicating methods to monitor degradation pathways
- Reference standards & method validation
11:40
Solution Provider
Reserved for Solution Provider
12:10
Digitalisation and Automation in QC Labs
- Integrating automated platforms for high-throughput analysis
- Real-time release testing: opportunities and limitations
- Predictive analytics and AI for process and product quality monitoring
- Data integrity, regulatory compliance, and digital record-keeping
14:00
Advanced Formulation Strategies for Stability, Efficacy and Developability of Biologics and Complex Modalities
- Designing robust formulations to improve stability and shelf-life of biologics and advanced therapies
- Managing aggregation, viscosity, and degradation challenges in high-concentration formulations
- Selecting optimal excipients and buffer systems for antibodies, ADCs, and novel modalities
- Integrating developability assessments early to reduce downstream formulation risks
14:30
Solution Provider
Reserved for Solution Provider
15:00
Innovative Drug Delivery Approaches for Next-Generation Biologics and Targeted Therapies
- Advancing delivery technologies for improved tissue targeting and therapeutic efficiency
- Overcoming biological barriers to enhance bioavailability and intracellular delivery
- Evaluating delivery systems such as nanoparticles, LNPs, and sustained-release platforms
- Aligning formulation design with clinical performance and patient-centric delivery requirements
16:00
Roundtable Discussion
AI-Powered Drug Discovery & Digital Innovation
Next-Generation TIDES Modalities & Therapeutic Innovation
Advanced Delivery Technologies & Targeted Therapeutic Systems
Partnering for Success: The Future of Pharma-Biotech Collaboration in TIDES
DAY 2
18 February 2027
08:50
Chairman’s Welcome Address
09:00
New Approach to Recombinant Peptides
- Next-generation recombinant peptide manufacturing
- Scaling peptide production efficiently
- Advances in purification & analytics
- Integrated CMC for recombinant peptides
Dr. Cecile Brocard
Head of Downstream Development, Boehringer Ingelheim, Austria
09:30
Solution Provider
Reserved for Solution Provider
10:00
Process Optimisation and Continuous Improvement for Complex Peptides and Oligonucleotides
- Process intensification strategies for complex peptides and oligonucleotides
- Implementing digital tools and automation to enhance process control
- Reducing variability and improving reproducibility across batches
- Lessons learned from troubleshooting scale-up challenges
11:10
Panel Discussion
Building Resilient and Agile Supply Chains for Biologics, Oligos and Peptides
- Strengthening end-to-end supply chain resilience in a volatile global environment
- Managing cold chain, logistics and distribution risks for complex modalities
- Improving visibility and digitalisation across global supply networks
- Aligning supply chain strategy with clinical, scale-up and commercial demand
11:40
Solution Provider
Reserved for Solution Provider
12:10
Strategic Outsourcing Models and CDMO Partnerships for Efficient Manufacturing
- Selecting the right CDMO partners across development and commercial stages
- Balancing in-house capabilities vs outsourcing for cost, speed and flexibility
- Strengthening governance, quality oversight and performance management of CDMOs
- Optimising tech transfer and collaboration models for seamless external manufacturing
Dr. Ulrich Rümenapp
Senior Biotech Program Lead, Bayer, Germany
14:00
Process Scale-Up Strategies for Efficient and Reproducible Oligonucleotide and Peptide Manufacturing
- Transitioning from lab-scale synthesis to GMP and commercial-scale manufacturing
- Managing scale-dependent challenges in solid-phase synthesis and purification
- Ensuring process robustness, reproducibility and batch-to-batch consistency
- Establishing scalable manufacturing platforms for clinical and commercial supply
14:30
Solution Provider
Reserved for Solution Provider
15:00
Overcoming Manufacturing and Quality Challenges in Large-Scale Oligo and Peptide Production
- Addressing impurity control and purification challenges during scale-up
- Optimising yield, cycle time and cost of goods (COGS) in large-scale production
- Ensuring analytical consistency and quality control across manufacturing scales
- Strengthening tech transfer and CDMO collaboration for seamless industrialisation
16:00
Integrated CMC Strategies for Efficient Development of Oligonucleotide and Peptide Therapeutics
- strategies from early development to commercial manufacturing
- Managing complexity in synthesis, purification and analytical control for oligos and peptides
- Aligning process development with regulatory expectations and quality requirements
- Enabling scalable and robust manufacturing platforms for clinical and commercial success
Hagen Cramer
Chief Technology Officer, QurAlis, USA
16:30
Advancing Fill-Finish Operations for Oligonucleotides and Peptides: Ensuring Quality and Scalability
- Overcoming fill-finish challenges for low-dose, high-potency oligonucleotide and peptide drugs
- Ensuring product stability and integrity during formulation, filling and packaging
- Selecting appropriate primary packaging systems for different delivery formats
- Scaling aseptic fill-finish processes from clinical to commercial production
BIG PHARMA
Volker Derdau
Head Center of Excellence Isotope Chemistry, Senior Distinguished Scientist
Sanofi
Germany
BIG PHARMA
Baerbel Grossmann
Associate Director Global Regulatory Affairs CMC Biologics
Sanofi
Germany
BIG PHARMA
Daniel Hurni
Supply Chain Enterprise Capability Lead
Roche
Switzerland
BIG PHARMA
Dr. Ulrich Rümenapp
Senior Biotech Program Lead
Bayer
Germany
BIG PHARMA
Marion Hitchcock
Managing Director Gene & Cell Therapies Incubator
Bayer
Germany
Hagen Cramer
Chief Technology Officer
QurAlis
USA
BIG PHARMA
Dr. Cecile Brocard
Head of Downstream Development
Boehringer Ingelheim
Austria
Chris Baldwin
Vice President, Manufacturing and Supply
Resolution Therapeutics
UK
BIG PHARMA
Karoline Bechtold-Peters
Director Science & Technology - Scientific Office/Drug Product Development/Global Biologics & CGT
Novartis
Switzerland
BIG PHARMA
Bettina Knapp
Head of Digital Operations Drug Substance
Boehringer Ingelheim Pharma
Germany
BIG PHARMA
Alessio Epifanio
Director, Environmental Health, Safety & Sustainability
J&J Innovative Medicine
Italy
BIG PHARMA
Gulbengu Kuzgun Yuksel
Network Head of Quality Cell & Gene Therapy
Roche
Switzerland
CHAIRMAN
Nicoletta Loggia
Chief Technology Officer
Orchard Therapeutics
Switzerland
GOLD
Attendance from
Service & Solution Providers
20%
Attendance from
Biopharma & Big Pharma
80%
Decision Makers
Decision Makers
Others
By Geography
Thought Leadership Speaking
Panel Participation
Solution Showcases
Engagement and Visibility Opportunities
Branding and Digital Visibility
Exclusive Networking
Our DACH Series Partners
Dr Heiner Apeler
VP Head of Biologics Development
Bayer
Germany
The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.
John Bridgeman
CSO
Immunokey
UK
Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey’s development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal.
Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS
Switzerland
Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I’m excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!
Dr Andrew Kelly
Director, Manufacturing Technology
BMS
Ireland
Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators
Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW
Switzerland
A fantastic deep dive into the DACH region’s CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together.
Brian O'Connor
VP Global Quality
Orchard Therapeutics
UK
Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees.
Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda
Spain
Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!
Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche
Switzerland
I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants.
Terry Gray
Field Marketing Manager
Merck
I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.
Warren Roche
Senior Statistical Expert
Sanofi
Ireland
Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event
Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease
Ireland
Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event.
I hope we have opportunity to connect again in the future.
Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT
Ireland
Well done on a very informative and successful event.
Radisson Blu Hotel, London Heathrow
140 Bath Road, Harlington, Hayes UB3 5AW, UK
Travel Options
By London Underground
From Heathrow Airport
Taxi or Ride-Hailing
By Car
From Other UK Cities
Accommodation Options
Explore recommended hotels near the venue.
Venue Hotel
Radisson Blu Hotel, London Heathrow
140 Bath Road, Hayes, Middlesex, UB3 5AW
venue for this event
To book a room at this hotel, please click the button below
London Heathrow Mariott Hotel
Bath Road Heathrow, Airport, Hayes UB3 5AN
4 minute walk from venue
To book a room at this hotel, please click the button below
Ibis Style London Heathrow Airport
272 Bath Rd, London UB3 5AY
8 minute walk from venue
To book a room at this hotel, please click the button below
Premier Inn London Heathrow
15 Bath Rd, London TW6 2AB
5 minute drive from venue
To book a room at this hotel, please click the button below
Please find the booth allocation in the table below.
4
Alfa Laval
11
QuickSTAT
12
BSP Pharmaceuticals
14
AsTec Chemicals
17
Unchained Labs
19
Inprocess LSP
18
Kemwell Biopharma
